Loading clinical trials...
Loading clinical trials...
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder
Conditions
Interventions
Bitopertin
Placebo
+1 more
Locations
34
United States
Excell Research
Oceanside, California, United States
Stanford University School of Medicine
Stanford, California, United States
Yale University School of Medicine; Neuroscience Research Training Program
New Haven, Connecticut, United States
Compass Research North, LLC
Leesburg, Florida, United States
Medical Research Group of Central Florida
Orange City, Florida, United States
University of South Florida
St. Petersburg, Florida, United States
Start Date
December 31, 2012
Primary Completion Date
April 30, 2015
Completion Date
April 30, 2015
Last Updated
August 2, 2017
NCT06647589
NCT06804525
NCT04480918
NCT05467683
NCT03918577
NCT05623306
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions